Intrinsic Value of S&P & Nasdaq Contact Us

Innoviva, Inc. INVA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
86/100
6/7 Pass
SharesGrow Intrinsic Value
$42.36
+75.1%
Analyst Price Target
$37.67
+55.7%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Innoviva, Inc. (INVA) trades at a trailing P/E of 6.5, forward P/E of 12.6. Trailing earnings yield is 15.34%, forward earnings yield 7.91%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $35.76.

Criteria proven by this page:

  • VALUE (100/100, Pass) — P/E is below market average (6.5); PEG ≤ 1.0 — Peter Lynch undervalued (0.01); analyst target implies upside (+55.7%); earnings yield beats bond yields (15.34%).
  • PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield 15.34% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
  • Analyst consensus target $37.67 (+55.7% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 86/100 with 6/7 criteria passed.

SharesGrow 7-Criteria Score
86/100
SG Score
View full scorecard →
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
FUTURE
64/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
55/100
→ Income
GROWTH
83/100
→ Income
INCOME
100/100
→ Income

Valuation Snapshot — INVA

Valuation Multiples
P/E (TTM)6.5
Forward P/E12.6
PEG Ratio0.01
Forward PEGN/A
P/B Ratio1.51
P/S Ratio3.67
EV/EBITDA3.3
Per Share Data
EPS (TTM)$3.63
Forward EPS (Est.)$1.91
Book Value / Share$15.68
Revenue / Share$5.55
FCF / Share$2.60
Yields & Fair Value
Earnings Yield15.34%
Forward Earnings Yield7.91%
Dividend Yield0.00%
Graham Number$35.76
SharesGrow IV$42.36 (+75.1%)
Analyst Target$37.67 (+55.7%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 19.8 -0.05 -3.34 8.83 0.08%
2017 11.3 0.09 -6.25 6.99 0.02%
2018 4.5 0.02 11.46 6.74 0.00%
2019 9.1 -0.15 4.57 5.49 0.00%
2020 5.6 0.13 2.33 3.73 -
2021 5.3 0.11 3.41 3.61 -
2022 4.3 -0.82 1.63 2.79 -
2023 5.8 -1.20 1.56 3.38 -
2024 46.5 -0.53 1.57 3.03 -
2025 5.0 0.01 1.15 3.17 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $0.53 $133.57M $59.54M 44.6%
2017 $1.17 $217.22M $134.14M 61.8%
2018 $3.48 $261M $395.06M 151.4%
2019 $1.43 $261.02M $157.29M 60.3%
2020 $2.02 $336.79M $224.4M 66.6%
2021 $2.87 $391.87M $368.84M 94.1%
2022 $2.37 $331.34M $213.92M 64.6%
2023 $2.20 $310.46M $179.72M 57.9%
2024 $0.36 $358.71M $23.39M 6.5%
2025 $3.30 $425.13M $271.17M 63.8%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $1.91 $1.84 – $2.02 $439.36M $431.39M – $447.34M 2
2027 $2.21 $2.07 – $2.34 $495M $487.41M – $502.58M 2
2028 $2.00 $1.62 – $2.38 $543.05M $527.56M – $558.54M 2
2029 $2.72 $2.48 – $2.91 $607.94M $568.17M – $641.91M 1
2030 $1.84 $1.68 – $1.97 $654.34M $611.53M – $690.9M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message